Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
COVID-19 Current Therapy Market CAGR Outlook And Future Development
The covid-19 current therapy market has experienced a substantial reduction in its size over recent years. A projection indicates it will decrease from $2.35 billion in 2025 to $1.57 billion in 2026, registering a compound annual growth rate (CAGR) of -33.2%. This historical downturn is attributable to factors such as the abrupt onset of covid-19, elevated hospitalization rates, a scarcity of initial therapeutic choices, reduced government and healthcare initiatives, and fewer emergency drug authorizations.
The covid-19 current therapy market size is projected to experience a significant contraction over the coming years. It is forecast to decrease to $0.31 billion in 2030, with a compound annual growth rate (CAGR) of -33.2%. This projected decrease can be attributed to factors such as reduced adoption of telemedicine for covid-19 management and limited growth in home care services. Key trends anticipated during this period encompass the growing acceptance of antiviral and monoclonal antibody treatments, a rise in corticosteroid application for serious covid-19 instances, an uptick in home care and remote patient monitoring for covid-19, an increase in supplement and immune support treatments, and the incorporation of combination and experimental therapies into treatment strategies.
Get A Free Sample Report With In-Depth Market Insights:
COVID-19 Current Therapy Market Demand Drivers: What’s Powering Industry Growth?
The expansion of healthcare infrastructure is anticipated to drive the COVID-19 current therapy market forward. The healthcare industry encompasses sectors that provide products and services for patient care, including prevention, treatment, rehabilitation, and palliative support. This infrastructure is vital for the effective delivery of COVID-19 therapies, facilitating timely patient care, aiding research and clinical trials, and supplying essential resources for optimal treatment. Illustratively, data from the American Health Care Association showed that the number of hospitals in the US increased to 6,129 in May 2023, up from 6,093 in 2022. Furthermore, a May 2023 report by the Office for National Statistics indicated that healthcare spending in the UK rose significantly by 9.4% in nominal terms and 9.7% in real terms. Thus, the growth of the healthcare industry is a key factor in the expansion of the COVID-19 current therapy market.
COVID-19 Current Therapy Market Segments: Where Is Growth Concentrated?
The covid-19 current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others
Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal Agents
COVID-19 Current Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Companies heavily involved in the COVID-19 current therapy market are intensifying their efforts to launch pioneering products, including COVID-19 oral antiviral treatments, to secure a competitive advantage. Antiviral treatment encompasses medications designed to suppress the reproduction and dissemination of viruses inside the body. For example, in April 2024, Invivyd, a US-based company dedicated to creating antibody-based therapies for serious viral infectious diseases, provided an update on the release of PEMGARDA™. After securing emergency use authorization (EUA) from The U.S. Food and Drug Administration (FDA), PEMGARDA quickly entered commercial availability. This particular treatment is intended to prevent COVID-19 in individuals experiencing moderate-to-severe immune compromise.
COVID-19 Current Therapy Market Key Participants And Competitive Landscape
Major companies operating in the covid-19 current therapy market are Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, Thermo Fisher Scientific
View The Full COVID-19 Current Therapy Market Report:
COVID-19 Current Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America is the largest region in the COVID-19 current therapy market in 2025. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the covid-19 current therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
